Voyager Therapeutics (VYGR) Other Accumulated Expenses (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Other Accumulated Expenses data on file, last reported at $511000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses changed N/A year-over-year to $511000.0; the trailing twelve-month figure through Mar 2026 stood at $511000.0 (changed N/A YoY), and the FY2025 full-year result was $549000.0, down 54.29% from the prior year.
• Other Accumulated Expenses fell to $511000.0 in Q1 2026, from $549000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $7.0 million in Q3 2024 to a low of $511000.0 in Q1 2026.
• A 5-year average of $3.4 million and a median of $3.0 million in 2023 frame the typical range for Other Accumulated Expenses.
• Peak annual rise in Other Accumulated Expenses reached 124.69% in 2024, while the deepest fall reached 62.47% in 2024.
• Tracing VYGR's Other Accumulated Expenses over 5 years: stood at $2.8 million in 2022, then advanced by 12.99% to $3.2 million in 2023, then tumbled by 62.47% to $1.2 million in 2024, then slumped by 54.29% to $549000.0 in 2025, then decreased by 6.92% to $511000.0 in 2026.
• Business Quant data shows VYGR's Other Accumulated Expenses at $511000.0 in Q1 2026, $549000.0 in Q4 2025, and $1.2 million in Q4 2024.